Suppression of the Neoplastic Phenotype

  • John A. Wyke
  • A. Richard Green


The concept that neoplasia results from an accumulation of somatic mutations in the tumour lineage is heuristically extremely useful. Strong support for this hypothesis has been provided by the demonstration that suitably altered proto-oncogenes can induce a neoplastic phenotype when introduced into normal recipient cells. However, activated oncogenes that behave in this phenotypically “dominant” fashion have been detected so far in only a minority of tumours and therefore the genetic basis of neoplasia in most cancers remains obscure. There are at least four explanations for the frequent failure to implicate positively acting oncogenes.


Cell Hybrid Somatic Cell Hybrid Neoplastic Phenotype Avian Sarcoma Virus Phenotypic Reversion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anders F (1983) The biology of an oncogene, based upon studies in neoplasia in Xiphophorus. In: Neth R, Gallo R (eds) Modern trends in human leukemia 5. Springer, Berlin Heidelberg New York, p 186Google Scholar
  2. Benedict WF, Weissman BE, Mark C, Stanbridge EG (1984) Tumorigenicity of human HT 1080 fibrosarcoma x normal fibroblast hybrids: chromosome dosage dependency. Cancer Res 44: 3471–3479PubMedGoogle Scholar
  3. Chiswell DJ, Enrietto PJ, Evans S, Quade K, Wyke JA (1982a) Molecular mechanisms involved in morphological variation of avian sarcoma virus-infected rat cells. Virology 116: 428–440PubMedCrossRefGoogle Scholar
  4. Chiswell DJ, Gillespie DA, Wyke JA (1982b) The changes in proviral chromatin that accompany morphological variation in avian sarcoma virus-infected rat cells. Nucl Acids Res 10: 3967–3979PubMedCrossRefGoogle Scholar
  5. Comings DE (1973) A general theory of carcinogenesis. Proc Natl Acad Sci USA 70: 3324–3328PubMedCrossRefGoogle Scholar
  6. Craig RW, Sager R (1985) Suppression of tumorigenicity in hybrids of normal and oncogenetransformed CHEF cells. Proc Natl Acad Sci USA 82: 2062–2066PubMedCrossRefGoogle Scholar
  7. Dracopoli NC, Houghton AN, Old LJ (1985) Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogenicity. Proc Natl Acad Sci USA 82: 1470–1474PubMedCrossRefGoogle Scholar
  8. Dyson PJ, Quade K, Wyke JA (1982) Expression of the ASV src gene in hybrids between normal and virally transformed cells: specific suppression occurs in some hybrids but not others. Cell 30: 491–498PubMedCrossRefGoogle Scholar
  9. Dyson PJ, Cook PR, Searle S, Wyke JA (1985) The chromatin structure of Rous sarcoma proviruses is changed by factors that act in trans in cell hybrids. EMBO J 4: 413–420PubMedGoogle Scholar
  10. Gateff E (1978) Malignant neoplasms of genetic origin in Drosophila melanogaster. Science 200: 1448–1459PubMedCrossRefGoogle Scholar
  11. Green AR, Wyke JA (1985) Anti-oncogenes-a subset of regulatory genes involved in carcinogenesis? Lancet ii: 475–477CrossRefGoogle Scholar
  12. Griegel S, Traub O, Willecke K, Schafer R Suppression and reexpression of transformed phenotype in hybrids of Ha-ras 1 transformed Rat-1 cells and early passage rat embryo fibroblasts. SubmittedGoogle Scholar
  13. Guerrero I, Villasante A, Corces V, Pellicer A (1985) Loss of the normal N-ras allele in a mouse thymic lymphoma induced by a chemical carcinogen. Proc Natl Acad Sci USA 82: 7810–7814PubMedCrossRefGoogle Scholar
  14. van Heyningen V, Boyd PA, Seawright A, Fletcher JM, Fantes JA, Buckton KE, Spowart G, Porteous DJ, Hill RE, Newton MS, Hastie ND (1985) Molecular analysis of chromosome 11 deletions in aniridia-Wilms tumor syndrome. Proc Natl Acad Sci USA 82: 8592–8596PubMedCrossRefGoogle Scholar
  15. Klinger HP (1982) Suppression of tumorigenicity. Cytogenet Cell Genet 32: 68–84PubMedCrossRefGoogle Scholar
  16. Klinger HP, Shows TB (1983) Suppression of tumorigenicity in somatic cell hybrids. Human chromosomes implicated as suppressors of tumorigenicity in hybrids with Chinese hamster ovary cells. J Natl Cancer Inst 71: 559–569PubMedGoogle Scholar
  17. Knudson AG (1985) Hereditary cancer, oncogenes, and anti-oncogenes. Cancer Res 45: 1437–1443PubMedGoogle Scholar
  18. Marshall CJ, Dave H (1978) Suppression of the transformed phenotype in somatic cell hybrids. J Cell Sci 33: 171–190PubMedGoogle Scholar
  19. Noda M, Selinger Z, Scolnick EM, Bassin RH (1983) Flat revertants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes. Proc Natl Acad Sci USA 80: 5602–5606PubMedCrossRefGoogle Scholar
  20. Sager R (1985) Genetic suppression of tumor formation. Adv Cancer Res 44: 43–68PubMedCrossRefGoogle Scholar
  21. Stanbridge EJ, Der CJ, Doersen C-J, Nishimi RY, Peehl DM, Weissman BE, Wilkinson JE (1982) Human cell hybrids: analysis of transformation and tumorigenicity. Science 215: 252–259PubMedCrossRefGoogle Scholar
  22. Wyke JA, Beamand JA, Varmus HE (1980) Factors affecting phenotypic reversion of rat cells transformed by avian sarcoma virus. Cold Spring Harbor Symp Quant Biol XLIV: 1065–1075Google Scholar
  23. Yokota J, Tsunetsugu-Yokota Y, Battifora H, LeFevre C, Cline MJ (1986) Alterations of myc, myb, and ras Ha proto-oncogenes in cancers are frequent and show clinical correlation. Science 231: 261–265PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • John A. Wyke
  • A. Richard Green

There are no affiliations available

Personalised recommendations